Wells Fargo Sees Up to 52% Upside in 2 Stocks
I'm LongbridgeAI, I can summarize articles.Wells Fargo identifies PTC Therapeutics and Dick's Sporting Goods as top stock picks with significant upside potential. For PTC, driven by Sephience revenue growth and pipeline prospects, the bank maintains an Overweight rating with a $109 target, implying 52% upside. Regarding Dick's, despite margin pressure from the Foot Locker acquisition, Wells Fargo sees opportunity in back-to-school demand and cost controls, assigning an Overweight rating and a $240 target, suggesting 19% upside.
Wells Fargo is looking beyond mega-cap technology for the market's next winners, highlighting PTC Therapeutics and Dick's Sporting Goods as two stocks it believes can outperform from current levels. The calls come as stronger second-quarter earnings and broader market participation are giving investors more opportunities outside the handful of tech giants that drove much of the market's recent gains.
PTC Therapeutics is a commercial-stage biotechnology company focused on treatments for rare and serious diseases. Its portfolio includes eight approved medicines, while wholly owned phenylketonuria drug Sephience has emerged as its biggest revenue contributor, accounting for about 63% of product revenue in Q2.
PTC's fundamentals have accelerated sharply. Second-quarter revenue reached $360.5 million, up 101.5% year over year, while earnings swung to $0.92 per share from a $0.83 loss. Management also raised full-year revenue guidance to $1.18 billion to $1.28 billion.
Wells Fargo analyst Benjamin Burnett sees further upside from Sephience adoption and PTC's pipeline, maintaining an Overweight rating and $109 price target, implying roughly 52% upside from the cited share price.
Wells Fargo is also bullish on Dick's Sporting Goods despite near-term pressure following its Foot Locker acquisition. Dick's generated $5.17 billion of fiscal first-quarter revenue, up more than 62%, but adjusted EPS declined 14% as dilution and Foot Locker's lower margins weighed on profitability.
Analyst Ike Boruchow nevertheless rates DKS Overweight with a $240 target, implying 19% upside. His thesis hinges on back-to-school demand, Dick's post-World Cup sales trajectory and management's ability to protect earnings if consumer demand weakens.
Investors Takeaway
PTCT investors should focus on Sephience adoption, revenue growth and clinical updates from the NLRP3 and MSH3 programs. Continued commercial momentum could make Wells Fargo's target easier to justify, while slower uptake would increase dependence on pipeline success.
For Dick's, the crucial test is different: whether management can absorb Foot Locker's lower profitability while preserving earnings. Back-to-school sales, footwear traffic, margins and second-half cost controls should determine whether depressed valuation multiples become an opportunity or a warning sign.